Wall Street analysts predict that Homology Medicines Inc (NASDAQ:FIXX) will announce $400,000.00 in sales for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Homology Medicines’ earnings, with the lowest sales estimate coming in at $300,000.00 and the highest estimate coming in at $500,000.00. Homology Medicines reported sales of $980,000.00 during the same quarter last year, which would suggest a negative year over year growth rate of 59.2%. The company is expected to announce its next earnings results on Tuesday, March 10th.
According to Zacks, analysts expect that Homology Medicines will report full-year sales of $1.43 million for the current financial year, with estimates ranging from $1.20 million to $1.60 million. For the next financial year, analysts anticipate that the firm will post sales of $12.60 million, with estimates ranging from $1.20 million to $24.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that follow Homology Medicines.
A number of analysts have weighed in on the stock. BidaskClub raised shares of Homology Medicines from a “sell” rating to a “hold” rating in a research note on Friday, February 7th. FIX assumed coverage on shares of Homology Medicines in a research note on Thursday, October 31st. They set a “market perform” rating on the stock. ValuEngine raised shares of Homology Medicines from a “hold” rating to a “buy” rating in a research note on Friday, January 3rd. Chardan Capital started coverage on shares of Homology Medicines in a research note on Monday. They set a “buy” rating and a $34.00 target price on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $36.00 price objective on shares of Homology Medicines in a research note on Thursday, February 6th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $31.83.
In related news, CFO W Bradford Smith sold 6,000 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $16.21, for a total value of $97,260.00. Following the sale, the chief financial officer now owns 6,000 shares of the company’s stock, valued at $97,260. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, major shareholder James E. Flynn sold 8,857 shares of the business’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $15.45, for a total transaction of $136,840.65. The disclosure for this sale can be found here. In the last three months, insiders sold 809,306 shares of company stock worth $13,748,904. 33.40% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently modified their holdings of the business. Great West Life Assurance Co. Can bought a new stake in Homology Medicines during the fourth quarter valued at $28,000. Marshall Wace LLP bought a new stake in Homology Medicines during the first quarter valued at $74,000. Bank of Montreal Can boosted its position in Homology Medicines by 42.8% during the fourth quarter. Bank of Montreal Can now owns 3,105 shares of the company’s stock valued at $64,000 after acquiring an additional 930 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in Homology Medicines by 404.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,320 shares of the company’s stock valued at $69,000 after acquiring an additional 2,662 shares during the last quarter. Finally, Quantbot Technologies LP bought a new stake in Homology Medicines during the fourth quarter valued at $77,000. 82.65% of the stock is currently owned by institutional investors and hedge funds.
Homology Medicines Company Profile
Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.
See Also: What does the Dogs of the Dow mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.